This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | MicrobiomeTrials
← Back to trials NCT07572136
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-29Est. Completion: 2030-06-30
Enrollment target: 57 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Ovarian Cancer Recurrent Ovarian Cancer Platinum Resistant Ovarian Cancer
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and als…
Detroit, United States Completed Sep 30, 2026
Rifampicin-Resistant Pulmonary Tuberculosis Multidrug-Resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tol…
Beijing, China Est. completion Sep 29, 2028
Relapsed Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia Pediatric Cancer Pediatric ALL, Relapsed Pediatric ALL Pediatric ALL, B Cell Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Pediatric AML R/R AML R/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple Locations Est. completion Apr 30, 2030